SMN1 and proximal spinal muscular atrophy: A driving rationale for considering gene-focused therapies in the most severe forms of ASD derives in part from recent progress in the treatment of spinal muscular atrophy (SMA)—a debilitating and progressive neuromuscular disorder caused by mutations in the SMN1 gene that is the most common genetic cause of infant death.